Sign in to continue:

Monday, July 27th, 2026

Scholar Rock Holding Corporation Files Form 8-K with SEC on June 4, 2026 – Corporate Information and Shareholder Actions

Scholar Rock Holding Corporation Announces Results of 2026 Annual Meeting of Stockholders

Cambridge, MA, June 4, 2026 – Scholar Rock Holding Corporation (“Scholar Rock” or the “Company”, NASDAQ: SRRK), a leading biotechnology company, has released the results of its 2026 Annual Meeting of Stockholders held on June 4, 2026. The meeting included several significant proposals with the potential to influence shareholder value, including director elections, the ratification of the independent auditor, and an advisory vote on executive compensation.

Key Highlights from the Annual Meeting

  • Election of Directors:

    • Shareholders elected the following individuals as Class II Directors for a three-year term, set to expire at the 2029 annual meeting:

      • Kristina Burow
    • Voting Results for Directors:

      • Votes For: 90,456,354
      • Votes Withheld: 14,598,794
      • Total Votes Cast: 105,055,148
    • The election of directors is a routine yet crucial event. The overwhelming support for the nominated directors indicates strong shareholder confidence in the current board and its strategic direction.
  • Ratification of Independent Auditor:

    • Deloitte & Touche LLP was ratified as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
    • Voting Results:

      • Votes For: 96,269,103
      • Votes Against: 14,916,507
      • Abstentions: 500,031
    • The reappointment of Deloitte & Touche LLP, a top-tier audit firm, signals continued focus on strong corporate governance and financial transparency.
  • Advisory Vote on Executive Compensation (“Say-on-Pay”):

    • Shareholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.
    • Voting Results:

      • Votes For: Not specified in the data, but proposal approved
      • Votes Against: Not specified
      • Abstentions: Not specified
    • The approval reflects shareholder support for the Company’s executive compensation policies and practices, which may be interpreted as a positive signal on management’s alignment with shareholder interests.

Other Noteworthy Details

  • Emerging Growth Company Status: Scholar Rock is no longer classified as an “Emerging Growth Company” under the SEC’s definitions.
  • No Pre-commencement or Soliciting Communications: The Company confirmed that the filing was not made in connection with written communications, soliciting material, or pre-commencement tender offers.
  • Corporate Details:

    • Address: 301 Binney Street, 3rd Floor, Cambridge, MA 02142
    • Phone: (857) 259-3860
    • SEC File Number: 001-38501
    • Tax ID: 82-3750435

Potential Impact on Shareholders and Share Price

  • The re-election of directors, ratification of the auditor, and approval of executive compensation are generally viewed as routine matters. However, the strong approval rates and lack of any major opposition suggest continued investor confidence in Scholar Rock’s leadership and direction.
  • There are no new material transactions, strategic shifts, or disclosures in this filing that would be considered price-sensitive or likely to move the share price in the immediate term.

Conclusion

Overall, Scholar Rock’s 2026 Annual Meeting delivered strong votes of confidence in the incumbent board, executive management, and auditor. While these results reinforce leadership stability and governance continuity, there were no new, price-sensitive disclosures or strategic surprises in this SEC filing.


Disclaimer: This article is a summary and analysis of Scholar Rock Holding Corporation’s SEC Form 8-K and is not investment advice. Investors should review the full filing and consult with their financial advisor before making any investment decisions. The information provided is based on the official filing and public data as of June 4, 2026, and may not reflect subsequent events or updates.

View Scholar Rock Holding Corp Historical chart here



Rallybio Corporation 2025 10-K: Clinical-Stage Rare Disease Biotech, Pipeline, Partnerships, and Regulatory Overview

Rallybio Corp 2025 Annual Report: Key Highlights and Price-S...

The Lovesac Company Files Form 8-K with SEC Detailing Company Information and NASDAQ Listing

The Lovesac Company Reports Results of 2026 Annual Meeting o...

FingerMotion Reports FY 2026 Financial Results: Revenue Declines 32% Amid Lower Telecom Segment Performance

FingerMotion Reports FY 2026 Financial Results: Key Highligh...